Filtered By:
Source: Thrombosis Research
Condition: Atrial Fibrillation

This page shows you your search results in order of date.

Order by Relevance | Date

Total 83 results found since Jan 2013.

D-dimer to fibrinogen ratio predicts early neurological deterioration in ischemic stroke with atrial fibrillation
The D-dimer to fibrinogen ratio (DFR) is a good indicator of clot-producing activity in thrombotic disease, but its clinical usefulness in stroke patients with nonvalvular atrial fibrillation (NVAF) has not been studied. We evaluated the association between the DFR and early neurological deterioration (END) in acute ischemic stroke (AIS) patients with NVAF.
Source: Thrombosis Research - July 31, 2023 Category: Hematology Authors: Ki-Woong Nam, Chi Kyung Kim, Sungwook Yu, Kyungmi Oh, Jong-Won Chung, Oh. Young Bang, Gyeong-Moon Kim, Jin-Man Jung, Tae-Jin Song, Yong-Jae Kim, Bum Joon Kim, Sung Hyuk Heo, Kwang-Yeol Park, Jeong-Min Kim, Jong-Ho Park, Jay Chol Choi, Man-Seok Park, Joon- Tags: Full Length Article Source Type: research

Barriers and facilitators for adherence to direct oral anticoagulants in patients with atrial fibrillation: A qualitative approach
Direct oral anticoagulants (DOACs) are the cornerstone for stroke prevention in patients with atrial fibrillation (AF) [1]. DOAC non-adherence and discontinuation have been associated with higher thromboembolic and mortality risks [2]. Until now, studies trying to optimise adherence to DOACs show disappointing results with limited effectiveness of interventions [3]. An explanation might be that medication (non-)adherence is a very complex behaviour in which different determinants, varying between patients, play a role.
Source: Thrombosis Research - June 14, 2023 Category: Hematology Authors: Andreas Capiau, Maxim Grymonprez, Sophie Scheire, Yenna Faute, Lies Lahousse, Els Mehuys, Tine De Backer, Koen Boussery Tags: Letter to the Editors-in-Chief Source Type: research

Clinical effectiveness and safety of edoxaban in obese patients — Results of the prospective Dresden NOAC Registry (NCT01588119)
Edoxaban is a direct factor Xa inhibitors approved for stroke prevention in atrial fibrillation (SPAF) and for venous thromboembolism (VTE) treatment. Edoxaban is given in a fixed dosing regimen (with recommended dose reductions for patients with renal impairment or body weight  
Source: Thrombosis Research - June 2, 2023 Category: Hematology Authors: Luise Tittl, Christina K öhler, Sandra Marten, Christiane Naue, Kristina Fache, Laura Stanneck, Thomas Schreier, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research

Electronic alerts for ambulatory patients with atrial fibrillation not prescribed anticoagulation: A randomized, controlled trial (AF-ALERT2)
Despite widely available risk stratification tools, safe and effective anticoagulants, and guideline recommendations, anticoagulation for stroke prevention in atrial fibrillation (AF) is under-prescribed in ambulatory patients. To assess the impact of alert-based computerized decision support (CDS) on anticoagulation prescription in ambulatory patients with AF and high-risk for stroke, we conducted this randomized controlled trial.
Source: Thrombosis Research - May 10, 2023 Category: Hematology Authors: Gregory Piazza, Shelley Hurwitz, Umberto Campia, Behnood Bikdeli, Junyang Lou, Candrika D. Khairani, Antoine Bejjani, Julia E. Snyder, Mariana Pfeferman, Briana Barns, Samantha Rizzo, Alexandra Glezer, Samuel Z. Goldhaber Tags: Full Length Article Source Type: research

The pathogenesis of aging-induced left atrial appendage thrombus formation and cardioembolic stroke in mice is influenced by inflammation-derived matrix metalloproteinases
Elderly people without atrial fibrillation (AF) still have a high incidence of cardioembolic stroke, suggesting that thrombus formation within the left atrial appendage (LAA) may also occur in an AF-independent manner. In the present study, we explored the potential mechanisms for aging-induced LAA thrombus formation and stroke in mice. We monitored stroke events in 180 aging male mice (14 –24 months) and assessed left atrium (LA) remodeling by echocardiography at different ages. Mice that had stroke were implanted with telemeters to confirm AF.
Source: Thrombosis Research - April 25, 2023 Category: Hematology Authors: Ruopeng Tan, Mengyang Yuan, Lin Wang, Jingjie Liu, Guinan Jiang, Jiawei Liao, Yun-Long Xia, Xiaomeng Yin, Yang Liu Source Type: research

DOACs plasma levels in relation to clinical outcome. How far have we come?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - March 3, 2023 Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research

DOACs plasma levels in relation to clinical outcome. How far have wecome?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - March 3, 2023 Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research

Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and safety in routine care are increasing.
Source: Thrombosis Research - May 22, 2022 Category: Hematology Authors: Christina K öhler, Luise Tittl, Sandra Marten, Christiane Naue, Marianne Spindler, Laura Stannek, Kristina Fache, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research

Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state
Neutrophil extracellular traps (NETs) formation contributes to thrombosis but its role in atrial fibrillation (AF) is poorly explored. We investigated whether increased circulating NETs markers in relation to a hypercoagulable state can predispose to ischemic stroke in anticoagulated AF patients during long-term follow-up.
Source: Thrombosis Research - March 2, 2022 Category: Hematology Authors: Patrycja Mo łek, Michał Ząbczyk, Krzysztof P. Malinowski, Joanna Natorska, Anetta Undas Tags: Full Length Article Source Type: research

To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin
Anticoagulation is widely used in the inpatient setting for various indications for both surgical and medical patients including stroke prevention in non-valvular atrial fibrillation, prevention of venous thromboembolism in post-surgical patients, management of acute coronary syndromes, and treatment of acute thrombosis. For patients with acute thrombosis, anticoagulation is the key therapy to stabilize the thrombus, prevent extension, and to prevent development of new thrombosis while risk factors are present [1].
Source: Thrombosis Research - November 21, 2021 Category: Hematology Authors: Nathan T. Connell, Katelyn W. Sylvester Tags: Editorial Source Type: research

Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics
Atrial fibrillation (AF) confers the major risk for ischemic stroke and systemic embolism [1]. Although anticoagulants can reduce the risk of AF-associated stroke, thromboembolic events, and mortality [2,3], a major drawback is the increased the risk of bleeding [4,5]. The overall risks and benefits must be carefully considered when selecting the most appropriate antithrombotic therapy, and for this reason, accurate bleeding risk stratification is needed. In clinical practice, various bleeding risk scores have been proposed and validated to assess the risk of bleeding in AF patients receiving oral anticoagulants (OAC).
Source: Thrombosis Research - November 8, 2021 Category: Hematology Authors: Sun Young Choi, Moo Hyun Kim, Sung-Cheol Yun Tags: Letter to the Editors-in-Chief Source Type: research

Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia
Due to advancements in hemophilia care, the overall life expectancy of persons with hemophilia is almost approaching that of the general population [1]. As a result, a growing population of elderly hemophilia patients is now prone to the same age-related cardiovascular comorbidities, such as coronary artery disease (CAD) and atrial fibrillation (AF) [2,3]. The management of AF is a challenge as antithrombotic therapy, the standard of care, is usually contraindicated in persons with hemophilia. Left atrial appendage occlusion (LAAO) is an alternative option for stroke prevention in patients with AF with a contraindication t...
Source: Thrombosis Research - August 4, 2021 Category: Hematology Authors: Ming Y. Lim, Mouhamed Yazan Abou-Ismail Tags: Letter to the Editors-in-Chief Source Type: research

Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research

5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselected cohorts.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf Tags: Full Length Article Source Type: research

Peak plasma rivaroxaban levels in patients weighing 120  kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research